NUCLEXPO, created in 2015 (United States), from 5 sister brands and 2214 competing brands. The NUCLEXPO brand is owned by Karyopharm Therapeutics, a company listed in New York. NUCLEXPO is part of the Biotechnology activity sector.
Investment simulator :
Portfolio valuation
Karyopharm Therapeutics
(NUCLEXPO)
over 5 years*
USD 0.38